242 related articles for article (PubMed ID: 33772327)
41. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
[TBL] [Abstract][Full Text] [Related]
42. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.
Roux S; Massicotte MH; Huot Daneault A; Brazeau-Lamontagne L; Dufresne J
Bone; 2019 Mar; 120():482-486. PubMed ID: 30572144
[TBL] [Abstract][Full Text] [Related]
43. A case of recalcitrant fibrous dysplasia treated with denosumab.
Gautam KP; Rajan R; Cherian KE; Kapoor N; Hephzibah J; Paul TV
Joint Bone Spine; 2020 Jul; 87(4):369-370. PubMed ID: 32279999
[No Abstract] [Full Text] [Related]
44. Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial.
Chapurlat R; Gensburger D; Trolliet C; Rouanet S; Mehsen-Cetre N; Orcel P
Bone; 2022 Apr; 157():116343. PubMed ID: 35104665
[TBL] [Abstract][Full Text] [Related]
45. Clinical guidelines for the management of craniofacial fibrous dysplasia.
Lee JS; FitzGibbon EJ; Chen YR; Kim HJ; Lustig LR; Akintoye SO; Collins MT; Kaban LB
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S2. PubMed ID: 22640797
[TBL] [Abstract][Full Text] [Related]
46. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Wang R; Renouf DA
Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
[TBL] [Abstract][Full Text] [Related]
47. Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
Sydlik C; Dürr HR; Pozza SB; Weißenbacher C; Roeb J; Schmidt H
World J Pediatr; 2020 Oct; 16(5):520-527. PubMed ID: 32776272
[TBL] [Abstract][Full Text] [Related]
48. Medical therapy in adults with fibrous dysplasia of bone.
Chapurlat RD
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P114-9. PubMed ID: 17228999
[TBL] [Abstract][Full Text] [Related]
49. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
50. Fibrous dysplasia in children and its management.
Gun ZH; Arif A; Boyce AM
Curr Opin Endocrinol Diabetes Obes; 2024 Feb; 31(1):60-66. PubMed ID: 38010041
[TBL] [Abstract][Full Text] [Related]
51. Craniofacial fibrous dysplasia associated with McCune-Albright syndrome: challenges in diagnosis and treatment: case reports.
Kabali TM; Moshy JR; Owibingire SS; Sohal KS; Simon ENM
BMC Oral Health; 2019 Aug; 19(1):180. PubMed ID: 31395055
[TBL] [Abstract][Full Text] [Related]
52. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
53. Zoledronic Acid in a Mouse Model of Human Fibrous Dysplasia: Ineffectiveness on Tissue Pathology, Formation of "Giant Osteoclasts" and Pathogenetic Implications.
Corsi A; Palmisano B; Spica E; Di Filippo A; Coletta I; Dello Spedale Venti M; Labella R; Fabretti F; Donsante S; Remoli C; Serafini M; Riminucci M
Calcif Tissue Int; 2020 Dec; 107(6):603-610. PubMed ID: 32875378
[TBL] [Abstract][Full Text] [Related]
54. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
55. Denosumab for Fibrous Dysplasia: Promising, but Questions Remain.
Collins MT; de Castro LF; Boyce AM
J Clin Endocrinol Metab; 2020 Nov; 105(11):e4179-80. PubMed ID: 32478399
[No Abstract] [Full Text] [Related]
56. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
Parisi MS; Oliveri B; Mautalen CA
Bone; 2003 Oct; 33(4):582-8. PubMed ID: 14555262
[TBL] [Abstract][Full Text] [Related]
57. McCune-Albright syndrome with craniofacial dysplasia: Clinical review and surgical management.
Belsuzarri TA; Araujo JF; Melro CA; Neves MW; Navarro JN; Brito LG; Pontelli LO; de Abreu Mattos LG; Gonçales TF; Zeviani WM
Surg Neurol Int; 2016; 7(Suppl 6):S165-9. PubMed ID: 27057395
[TBL] [Abstract][Full Text] [Related]
58. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
59. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Tsourdi E; Langdahl B; Cohen-Solal M; Aubry-Rozier B; Eriksen EF; Guañabens N; Obermayer-Pietsch B; Ralston SH; Eastell R; Zillikens MC
Bone; 2017 Dec; 105():11-17. PubMed ID: 28789921
[TBL] [Abstract][Full Text] [Related]
60. Dental characteristics of fibrous dysplasia and McCune-Albright syndrome.
Akintoye SO; Lee JS; Feimster T; Booher S; Brahim J; Kingman A; Riminucci M; Robey PG; Collins MT
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Sep; 96(3):275-82. PubMed ID: 12973283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
